Shreyaskumar R. Patel, MD .
Published Online:Feb 18, 2016.
What clinical data support the use of trabectedin in patients with myxoid liposarcoma?
There is data from our colleagues in Milan, the Italian Sarcoma Group and the National Cancer Institute in Milan where they have looked at a series of patients specifically with mixoid liposarcoma.
In the earlier days of the investigations with this drug have shown that the probability that you will get volumetric response, RECIST responses is very high, at least greater than 50%.
That has clearly born out in the subsequent trials in the vast experience in the public domain, looking at trabectedin in various types of sarcomas.
Mixoid liposarcoma now is recognized as one of the more sensitive subsets to Yondelis or trabectedin therapy.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
- In January of 2014, he presents to his PCP with complaints of right lower leg pain of several weeks’ duration .
- Physical exam was unremarkable except for swelling of the lower right calf; x-ray of the affected leg was negative for fracture .
- MRI scan of the lower right calf showed a 20 cm well defined lobular mass arising between the gastrocnemius and soleus .
- Biopsy of the mass showed myxoid liposarcoma with round cell component. Patient underwent en bloc resection of the tumor following preoperative radiotherapy .
- Gross examination showed the tumor to be 10 × 8 × 15 cm with gelatinous brownish appearance .
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.
- In May of 2015, he returns for follow up with intermittent chest and lower back pain; CT scan is consistent with progression of the mediastinal and perinephric masses, and bone scan shows new lesions occurring in the L2 and L3 lumbar vertebrae .
- At recurrence, liver and renal function and CBC are within normal limits, and his ECOG performance status is 1 .
- He received treatment with trabectedin (1.5 mg/m2 24-hr infusion given every 3 week) .
- At the 2nd cycle he develops febrile neutropenia (ANC< 500 cells/mm3) requiring hospitalization .
- The oncologist reduces his trabectedin dose to 1.2 mg/m2; he continues therapy .
- Within 1 week, he shows clinical improvement and CT scan shows slight improvement .
